Pharmacology

Biography

Biography: Ali Sheikh Md Sayed

Abstract

Acute myocardial infarction (AMI) is the leading cause of sudden cardiac death (SCD) in the world and remains a significant unsolved clinical issue. Prevalence of AMI event will increase ≈18% by 2030. Though, in 20^th century, enormous progress has been made in the diagnosis, treatment, and prognosis of AMI but still there is a clinical demand for a novel diagnostic, prognostic biomarker and new therapeutic interventions to decrease the AMI incidence. The purpose of this study was to evaluate the diagnostic and prognostic value of circulating miRNAs as a biomarker for AMI patients, and therapeutic effect of miR-208b or miR-378 in cardiac cell during hypoxia-reoxygenation (HR) injury. In our study, we enrolled AMI patients, 12 week-old C57BL/6 mice AMI and H9c2 cells. Total RNA was isolated from plasma and H9c2 cells by using TRIZOL reagent. Circulating miRNAs levels were measured by quantitative real-time polymerase chain reaction. We found that circulating miR-208b, miR-499 and miR-765 levels were significantly up-regulated, whereas miR-149, miR-378 and miR-424 levels were markedly down-regulated both in AMI patients and Mice model of AMI compared with controls, (p<0.01). Plasma levels of these miRNAs were returned towards normal at 96 h after PCI (p<0.01). However, inhibition of miR-208b and over expression of miR-378 were dramatically increased cell survival through negative regulation of their targets in HR-induced cardiomyocyte injury cell. Our study demonstrated that circulating miRNAs represent as novel diagnostic and prognostic biomarkers for AMI patients, and also represents a new therapeutic approach for ischemic heart disease.